phenylalanine has been researched along with sar 1118 in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (63.89) | 24.3611 |
| 2020's | 13 (36.11) | 2.80 |
| Authors | Studies |
|---|---|
| Burnier, JP; Gadek, TR; Haughey, DB; Newman, MS; O'Neill, CA; Semba, CP; Smith, VL; Swearingen, D | 1 |
| Do, DV; Gadek, TR; Gehlbach, P; Handa, JT; Nguyen, QD; Paskowitz, DM; Semba, C; Shaikh, O; Solomon, S; Stark, W | 1 |
| Gadek, TR; O'Neill, CA; Pearlman, E; Sun, Y; Zhang, R | 1 |
| Kompella, UB; Yandrapu, S | 1 |
| D'Ambrosio, FA; Eiferman, RA; Kennedy, KS; Lonsdale, JD; McLaurin, EB; Semba, CP; Sheppard, JD; Torkildsen, GL | 1 |
| Karpecki, P; Latkany, R; Luchs, J; Martel, J; Raychaudhuri, A; Sall, K; Semba, CP; Smith, V; Tauber, J | 1 |
| Haque, R; Perez, VL; Pflugfelder, SC; Shojaei, A; Zhang, S | 1 |
| Donnenfeld, ED; Karpecki, PM; Majmudar, PA; Nichols, KK; Raychaudhuri, A; Roy, M; Semba, CP | 1 |
| Paton, DM | 1 |
| Keating, GM | 1 |
| Holland, EJ; Jackson, MA; Karpecki, PM; Luchs, J; Nichols, KK; Raychaudhuri, A; Roy, M; Sall, K; Shojaei, A; Tauber, J | 1 |
| Asbell, PA; Kuklinski, E | 1 |
| Finn, LA; Hussar, DA | 1 |
| Hussar, DA | 1 |
| Donnenfeld, ED; Nattis, AS; Perry, HD; Rosenberg, ED | 1 |
| Abdullahi, M; Olotu, FA; Soliman, ME | 1 |
| de Paiva, CS; Guimaraes de Souza, R; Pflugfelder, SC; Stern, ME; Yu, Z | 1 |
| Kang, S; Kim, CE; Kim, K; Kleinman, HK; Ousler, GW; Sosne, G; Yang, J | 1 |
| Donnenfeld, ED; Hovanesian, JA; Karpecki, PM; Nichols, KK; Raychaudhuri, A; Shojaei, A; Zhang, S | 1 |
| Franko, J; Patel, J | 1 |
| Akpek, EK; Amescua, G; Dunn, SP; Farid, M; Garcia-Ferrer, FJ; Lin, A; Mah, FS; Musch, DC; Rhee, MK; Varu, DM | 1 |
| Chan, CC; Prokopich, CL | 1 |
| Gupta, PK; Passi, SF; Tong, AY | 1 |
| Chhabra, S; Conto, JE; Hamadani, M; Hari, PN; Jerkins, JH; Shah, NN; Zellner, K | 1 |
| Tauber, J | 1 |
| Lin, MC; Neri, P; Perez, VL; Periman, LM; Saban, DR | 1 |
| Arzeno, J; Holland, V; Lee, EY; Ni, C | 1 |
| Evans, DG; Karpecki, PM; Nichols, KK | 1 |
| Bailly, B; Day, CJ; Dirr, L; Guillon, P; Haselhorst, T; Jen, FE; Jennings, MP; Mak, J; Spillings, BL; von Itzstein, M | 1 |
| Mathew, R; Perez, VL; Saban, DR; Singh, PP; Yu, C | 1 |
| Baillif, S; Elmaleh, V; Ferrete, T; Loschi, M; Martel, A; Rocher, F; Tieulie, N | 2 |
| Schubert-Tennigkeit, AA | 1 |
| Barabino, S; Cohen, A; Donnenfeld, E; Figueiredo, FC; Holland, EJ; Jackson, MA; Piccolo, R; Rolando, M | 1 |
| Abbas, AA; Afshari, NA; Bahar, I; Bu, JJ; Cohen-Tayar, Y; Finburgh, EN; Hakim, DF; Lian, RR; Noguchi, T; Sella, R; Shaw, P; Zhao, J | 1 |
9 review(s) available for phenylalanine and sar 1118
| Article | Year |
|---|---|
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.
Topics: Cell Adhesion; Dry Eye Syndromes; Humans; Intercellular Adhesion Molecule-1; Lymphocyte Function-Associated Antigen-1; Phenylalanine; Sulfones | 2016 |
Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
Topics: Dry Eye Syndromes; Humans; Ophthalmic Solutions; Phenylalanine; Sulfones | 2017 |
Sjogren's syndrome from the perspective of ophthalmology.
Topics: Administration, Ophthalmic; Cyclosporine; Dry Eye Syndromes; Fatty Acids, Omega-3; Glucocorticoids; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Muscarinic Agonists; Ophthalmology; Phenylalanine; Pilocarpine; Punctal Plugs; Quinuclidines; Sjogren's Syndrome; Sulfones; Thiophenes | 2017 |
NewDrugs 2017, part 2.
Topics: Amides; Antibodies, Monoclonal, Humanized; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Therapy; gamma-Cyclodextrins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Peptides; Phenylalanine; Quinoxalines; Sofosbuvir; Sugammadex; Sulfonamides; Sulfones; Thioglycolates; Triazoles; United States; United States Food and Drug Administration | 2017 |
Lifitegrast for the treatment of dry eye disease in adults.
Topics: Adult; Clinical Trials as Topic; Dry Eye Syndromes; Humans; Lymphocyte Function-Associated Antigen-1; Ophthalmic Solutions; Phenylalanine; Quality of Life; Sulfones; Treatment Outcome | 2017 |
Dry Eye Syndrome Preferred Practice Pattern®.
Topics: Academies and Institutes; Cyclosporine; Diagnostic Techniques, Ophthalmological; Dry Eye Syndromes; Humans; Immunosuppressive Agents; Ophthalmic Solutions; Ophthalmology; Phenylalanine; Physical Examination; Practice Patterns, Physicians'; Sulfones; United States | 2019 |
Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
Topics: Animals; Clinical Trials as Topic; Dry Eye Syndromes; Humans; Ophthalmic Solutions; Phenylalanine; Sulfones; Treatment Outcome | 2019 |
The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
Topics: Administration, Topical; Clinical Decision-Making; Cyclosporine; Dry Eye Syndromes; Goblet Cells; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Inflammation; Integrins; Intercellular Adhesion Molecule-1; Lacrimal Apparatus; Lymphocyte Function-Associated Antigen-1; Phenylalanine; Steroids; Sulfones; T-Lymphocytes; Tears | 2020 |
A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
Topics: Administration, Ophthalmic; Clinical Trials as Topic; Cyclosporine; Dry Eye Syndromes; Emulsions; Humans; Ophthalmic Solutions; Pharmaceutical Vehicles; Phenylalanine; Sulfones | 2021 |
8 trial(s) available for phenylalanine and sar 1118
| Article | Year |
|---|---|
Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Sulfones; Tears; Young Adult | 2011 |
Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.
Topics: Adult; Aqueous Humor; Diabetic Retinopathy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lymphocyte Function-Associated Antigen-1; Macular Edema; Male; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Receptors, Lymphocyte Homing; Sulfones; Vitreous Body | 2012 |
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Conjunctiva; Cornea; Double-Blind Method; Dry Eye Syndromes; Female; Fluorescein; Fluorometry; Humans; Lissamine Green Dyes; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Staining and Labeling; Sulfones; Treatment Outcome; Young Adult | 2014 |
Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Topics: Adult; Aged; Aged, 80 and over; Cornea; Double-Blind Method; Dry Eye Syndromes; Female; Humans; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Sulfones; Tears; Treatment Outcome; Visual Acuity; Visual Analog Scale; Young Adult | 2015 |
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Dry Eye Syndromes; Female; Fluorophotometry; Humans; Intraocular Pressure; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Sulfones; Visual Acuity; Young Adult | 2016 |
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Topics: Adult; Aged; Double-Blind Method; Dry Eye Syndromes; Eye Pain; Female; Humans; Lymphocyte Function-Associated Antigen-1; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Sulfones; Visual Acuity | 2017 |
Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Sulfones; Treatment Outcome; Visual Analog Scale | 2019 |
A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction.
Topics: Aged; Aged, 80 and over; Dacryocystitis; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Meibomian Glands; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Single-Blind Method; Sulfones; Tears; Time Factors; Treatment Outcome; Visual Acuity | 2020 |
19 other study(ies) available for phenylalanine and sar 1118
| Article | Year |
|---|---|
Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118).
Topics: Animals; CD11a Antigen; CD18 Antigens; Contact Lenses; Cornea; Corneal Stroma; Disease Models, Animal; Eye Infections, Bacterial; Inflammation; Lymphocyte Function-Associated Antigen-1; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Confocal; Neutrophil Infiltration; Phenylalanine; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus; Sulfones | 2013 |
Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye.
Topics: Delayed-Action Preparations; Drug Delivery Systems; Drug Discovery; Eye Diseases; Lymphocyte Function-Associated Antigen-1; Microspheres; Phenylalanine; Sulfones; Vascular Diseases | 2013 |
Lifitegrast (Xiidra) for dry eye disease.
Topics: Administration, Ophthalmic; Anti-Inflammatory Agents; Drug Administration Schedule; Dry Eye Syndromes; Humans; Lymphocyte Function-Associated Antigen-1; Ophthalmic Solutions; Phenylalanine; Sulfones; Treatment Outcome | 2016 |
Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
Topics: Anti-Inflammatory Agents; Clinical Studies as Topic; Drug Evaluation, Preclinical; Dry Eye Syndromes; Humans; Inflammation; Intercellular Adhesion Molecule-1; Lymphocyte Function-Associated Antigen-1; Ophthalmic Solutions; Phenylalanine; Sulfones; T-Lymphocytes | 2016 |
2017 New Drug Update.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Drugs, Investigational; Dry Eye Syndromes; Gout Suppressants; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Peptides; Phenylalanine; Piperidines; Sulfones; Thioglycolates; Triazoles; Urea | 2017 |
Allosteric inhibition abrogates dysregulated LFA-1 activation: Structural insight into mechanisms of diminished immunologic disease.
Topics: Allosteric Regulation; Humans; Immune System Diseases; Ligands; Lymphocyte Function-Associated Antigen-1; Molecular Dynamics Simulation; Molecular Structure; Phenylalanine; Structure-Activity Relationship; Sulfones | 2018 |
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.
Topics: Animals; Chemokine CXCL11; Chemokine CXCL9; Dry Eye Syndromes; Female; Inflammation; Interferon-gamma; Keratoconjunctivitis Sicca; Mice; Mice, Inbred C57BL; Ophthalmic Solutions; Phenylalanine; Sulfones; Th1 Cells | 2018 |
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Topics: Animals; Conjunctiva; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Female; Goblet Cells; Humans; Inflammation Mediators; Lacrimal Apparatus; Male; Mice; Mice, Inbred NOD; Mucins; Ophthalmic Solutions; Phenylalanine; Polyphosphates; Prescription Drugs; Scopolamine; Sulfones; Tears; Thymosin; Treatment Outcome; Uracil Nucleotides | 2018 |
Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease.
Topics: Administration, Ophthalmic; Humans; Keratoconjunctivitis Sicca; Ophthalmic Solutions; Phenylalanine; Randomized Controlled Trials as Topic; Sulfones | 2018 |
Clinical Outcomes of Lifitegrast 5% Ophthalmic Solution in the Treatment of Dry Eye Disease.
Topics: Adult; Aged; Aged, 80 and over; Conjunctiva; Cornea; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Lymphocyte Function-Associated Antigen-1; Male; Matrix Metalloproteinase 9; Middle Aged; Ophthalmic Solutions; Phenylalanine; Retrospective Studies; Sulfones; Tears; Treatment Outcome; Young Adult | 2020 |
Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease.
Topics: Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Keratoconjunctivitis Sicca; Phenylalanine; Prospective Studies; Retrospective Studies; Sulfones | 2020 |
Ocular lichen planus treated with lifitegrast.
Topics: Eye; Humans; Lichen Planus; Phenylalanine; Sulfones | 2021 |
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Topics: Aminopyridines; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Benzodioxoles; Cell Line; Chlorocebus aethiops; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; Evans Blue; Humans; Molecular Docking Simulation; Phenylalanine; Protein Binding; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Sulfones; Surface Plasmon Resonance; Vero Cells; Virus Attachment; Virus Replication | 2021 |
Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model.
Topics: Animals; Dry Eye Syndromes; Eyelid Diseases; Humans; Hypersensitivity; Immunity; Lymphocyte Function-Associated Antigen-1; Meibomian Gland Dysfunction; Meibomian Glands; Mice; Phenylalanine; Sulfones; Tears | 2021 |
Eye amputation following lifitegrast treatment for ocular graft-versus-host disease: First case report.
Topics: Aged; Amputation, Surgical; Dry Eye Syndromes; Graft vs Host Disease; Humans; Phenylalanine; Sulfones | 2021 |
Eye amputation following lifitegrast treatment for ocular graft-versus-host disease - Response to Novartis.
Topics: Amputation, Surgical; Graft vs Host Disease; Humans; Phenylalanine; Sulfones | 2021 |
Eye amputation following lifitegrast treatment for ocular graft-versus-host disease - Response from the Xiidra® product owner.
Topics: Amputation, Surgical; Graft vs Host Disease; Humans; Phenylalanine; Sulfones | 2021 |
Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
Topics: Double-Blind Method; Dry Eye Syndromes; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Phenylalanine; Prospective Studies; Randomized Controlled Trials as Topic; Sulfones; Treatment Outcome | 2021 |
The Effect of Anti-Inflammatory Topical Ophthalmic Treatments on In Vitro Corneal Epithelial Cells.
Topics: Anti-Inflammatory Agents; Cyclosporine; Epithelial Cells; Humans; Ophthalmic Solutions; Phenylalanine; Sulfones; Tacrolimus | 2022 |